1. New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

3. Introduction/Background

4. Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

5. Type 2 Diabetes and Cardiovascular Disease: Glucose-Plus Approach

6. Several Pathophysiologic Targets in T2DM

7. Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

8. New Paradigm for Treating the Patient With Both T2DM and CVD

9. Decision Plan for Patient-Centered Glycemic Management in Type 2 Diabetes

10. Molecular Structure: GLP-1, Liraglutide, Dulaglutide, Albiglutide, Exenatide, Lixisenatide, and Semaglutide

11. Pleiotropic Effects of Selected GLP-1 RAs: Liraglutide and the LEADER Trial

12. Integrated Analysis of 6 DURATION Trials: Exenatide Once Weekly

13. Albiglutide: HARMONY Clinical Trial Program

14. Dulaglutide Clinical Program: HbA1c Change From Baseline Across Various Trials

15. Dulaglutide Clinical Program: Weight Change From Baseline Across Various Trials

16. Results From SUSTAIN 1-5: Change in HbA1c

17. Results From SUSTAIN 1-5: Change in Body Weight

18. SUSTAIN 7: Changes in HbA1c and Body Weight, Semaglutide vs Dulaglutide

19. Primary Endpoint Results From the LEADER Trial *

20. EMPA-REG OUTCOME: Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

21. HARMONY OUTCOMES Primary Endpoint Results: Time to CV Death, MI or Stroke (MACE)

22. LEADER: Results for CV Death

23. SUSTAIN-6 (Semaglutide): Primary Outcome Results

24. REWIND: Dulaglutide Topline Results

25. Sodium Salcaprozate (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) Oral Absorption Promoter

26. PIONEER 2 and 3 Topline Results

27. PIONEER 6: Topline Results For Cardiovascular Outcomes

28. Summary and Conclusions

29. Abbreviations

30. Abbreviations (cont)